realfast95 Thursday, 01/02/20 04:27:05 PM Re: None Post # of 293 competition failed Phase 2. We will run a Phase 3 in 2020 for psoriasis DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis CUPERTINO, Calif., Jan. 2, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis. Twenty-two patients completed the study, applying DUR-928 topically to the plaque on one arm and the vehicle (placebo) to a similar plaque on the other arm daily for 28 days. DUR-928 did not demonstrate a benefit over vehicle (placebo) based on Investigator's Global Assessment (IGA), which was the scoring system for the primary analysis, or in any of the secondary analyses. Daily topical application of DUR-928 was well tolerated with no meaningful differences in adverse events between the treatment and vehicle (placebo) groups. There were no AEs attributed to the study drug. "Based on the top-line data, we do not plan to continue development of topical DUR-928 in psoriasis," said James E. Brown, President and CEO of DURECT.